Uplizna appeared to benefit patients with neuromyelitis optica spectrum disorder who were previously treated with rituximab, according to study results published in Multiple Sclerosis and Related Disorders.
“Rituximab is an anti-CD20 B-cell-depleting agent that has historically been used to help prevent attacks in neuromyelitis optica spectrum disorder (NMOSD),” Eoin P. Flanagan, MB, BCh, a neurologist at Mayo Clinic, told Healio Neurology. “Uplizna (inebilizumab; Horizon Therapeutics) is a recently approved medicine that targets and depletes CD19-expressing B cells,